

# Monte Carlo for variability simulation and uncertainty

Caroline L. Ring



*The views expressed in this presentation are those of the author(s)  
and do not necessarily reflect the views or policies of the U.S. EPA.*

# Overview

- Uncertainty vs. Variability in HTTK model parameters
- Characterizing key uncertainty in chemical-specific TK parameters
  - Fraction unbound in plasma protein ( $F_{up}$ )
  - Intrinsic hepatic clearance rate ( $Cl_{int}$ )
- Characterizing variability: HTTK-Pop for human TK variability
- Relative contributions of uncertainty and variability to TK model predictions
- Simulating sensitive subpopulations

# Uncertainty vs. variability in HHTK model parameters


# Review: HTK model parameters

Chemical-specific parameters	
Intrinsic hepatic clearance rate (CL <sub>int</sub> )	Measured in HT <i>in vitro</i> assays (Rotroff <i>et al.</i> 2010; Wetmore <i>et al.</i> 2012, 2014, 2015; Wambaugh <i>et al.</i> 2019) or predicted <i>in silico</i> (Sipes <i>et al.</i> 2017)
Fraction unbound to plasma protein (F <sub>up</sub> )	
Tissue:blood partition coefficients (for compartmental models)	Predict from phys-chem properties and tissue properties (Pearce <i>et al.</i> , 2017)
Physiological parameters	
Tissue masses (including body weight)	Gathered from data available in the published literature [Wambaugh <i>et al.</i> 2015; Pearce <i>et al.</i> 2017a]
Tissue blood flows	
Glomerular filtration rate (passive renal clearance)	
Hepatocellularity	


# Chemical-specific parameters measured *in vitro* carry measurement uncertainty

Chemical-specific parameters	
Intrinsic hepatic clearance rate (CL <sub>int</sub> )	Measured in HT <i>in vitro</i> assays (Rotroff <i>et al.</i> 2010; Wetmore <i>et al.</i> 2012, 2014, 2015; Wambaugh <i>et al.</i> 2019)
Fraction unbound to plasma protein (F <sub>up</sub> )	

CL<sub>int</sub>: Cryo-preserved  
hepatocyte suspension  
Shibata *et al.* (2002)




F<sub>up</sub>: Rapid Equilibrium  
Dialysis (RED)  
Waters *et al.* (2008)



# Parameters represent biology — so they have population variability

Chemical-specific parameters	
Intrinsic hepatic clearance rate (CL <sub>int</sub> )	Represent chemical-body interactions — vary with individual genetics, environmental factors, age, etc.
Fraction unbound to plasma protein (F <sub>up</sub> )	
Tissue:blood partition coefficients (for compartmental models)	
Physiological parameters	
Tissue masses (including body weight)	Represent physiology — vary with individual genetics, environmental factors, age, etc.
Tissue blood flows	
Glomerular filtration rate (passive renal clearance)	
Hepatocellularity	

HTTK model parameters determine the slope relating  $C_{ss}$  to daily dose –  
need to propagate both uncertainty & variability



# Approach to uncertainty & variability: Monte Carlo

- Characterize uncertainty in chemical-specific parameters  $F_{up}$  and  $Cl_{int}$  in terms of probability distributions
- Characterize population variability in physiological parameters in terms of (correlated) probability distributions
- Draw samples from distributions: “simulated population”
- Evaluate HTK model for each “simulated individual” in the “simulated population”
- Describe resulting distribution of HTK model predictions




# Characterizing key uncertainty in chemical-specific TK parameters

# General approach to uncertainty quantification

Unknown true value


Observed (measured) value



# General approach to uncertainty quantification

Unknown true value

Observed (measured) value




Error

- Identify sources of error
- Develop mathematical model of error

# General approach to uncertainty quantification


Unknown true value

Observed (measured) value



Error

- Identify sources of error
- Develop mathematical model of error




## **Bayesian inference:**


Find a *distribution* of possible true values compatible with the observed values, under this error model

# Uncertainty in Fup

# Fup: How to measure *in vitro* using Rapid Equilibrium Dialysis (RED)




# Sources of measurement uncertainty: Mass spectrometry



<https://commons.wikimedia.org/wiki/File:ObwiedniaPeptydu.gif>  
(GPL)

Wambaugh et al. (2019)


- Instrument noise
- Limit of quantification (LOQ)
- Instrument calibration




Kkmurray, [CC BY-SA 3.0](https://commons.wikimedia.org/wiki/File:ObwiedniaPeptydu.gif) via Wikimedia Commons

# LOQ is a problem in the RED assay for highly-bound chemicals

**44%** of chemicals in Wambaugh et al. (2019)




<https://commons.wikimedia.org/wiki/File:ObwiedniaPeptydu.gif>  
(GPL)






Approach to <LOQ problem:  
Repeat RED assay with varying amounts of protein



Estimate dissociation constant  $K_d$   
(strength of binding affinity between chemical and protein)

# Additional source of uncertainty: Non-specific chemical binding to membrane or walls




# Bayesian inference model for Fup uncertainty

Unknown true value:  
Fup for a chemical




Observed (measured) value:  
MS peak areas for protein-  
free and protein-containing  
sides



Error

- MS noise
- MS calibration
- LOQ
- Non-specific binding




Wambaugh et al. (2019)

**Result:** *Distribution* of Fup values for a  
chemical

# Uncertainty in CLint

# CLint: How to measure *in vitro* using pooled human hepatocytes




Culture donated human hepatocytes from 10 adult volunteers


Add known amount of chemical

Measure chemical concentration remaining at 0, 15, 30, 60, and 120 minutes

CLint can be estimated from fitting a decaying exponential




# Mass spec uncertainties also apply to CLint




Kkmurray, [CC BY-SA 3.0](https://commons.wikimedia.org/wiki/File:ObwiedniaPeptydu.gif) via  
Wikimedia Commons

- Uncertainty in peak area
- LOQ
- Calibration curve


<https://commons.wikimedia.org/wiki/File:ObwiedniaPeptydu.gif>  
(GPL)




# Additional uncertainty source: Is chemical really metabolized at all?



# Additional uncertainty source: Saturable metabolism



Wambaugh et al. (2019)





# Bayesian inference model for Clint uncertainty


Unknown true value:  
Clint for a chemical

Observed (measured) value:  
MS peak areas at 5 time  
points

Error

- MS noise
- MS calibration
- LOQ
- Probability of no metabolism
- Probability of saturation

**Result:** *Distribution* of Clint values for a chemical



Wambaugh et al. (2019)

# Characterizing variability: HTTK- Pop for human TK variability

# HTTK physiological parameters

Physiological parameters
Tissue masses (including body weight)
Tissue blood flows
Glomerular filtration rate (passive renal clearance)
Hepatocellularity

# Data source for population physiology: CDC NHANES



CDC NHANES = Centers for Disease Control National Health and Nutrition Examination Survey

Large, representative, ongoing survey of US population: demographics, body measures, medical examination data....

## **NHANES does measure:**

Sex  
Age  
Height  
Weight  
Serum creatinine



## **NHANES does not measure:**

Tissue masses  
Tissue blood flows  
GFR (kidney function)  
Hepatocellularity

# Correlated Monte Carlo approach to simulating population variability in physiology: HTTK-Pop

*Sample* NHANES measured quantities for actual NHANES individuals (capturing covariance):

Sex  
Age  
Height  
Weight  
Serum creatinine



Regression equations from literature (McNally *et al.*, 2014) (+ residual marginal variability)

(Similar approach used in SimCYP [Jamei *et al.* 2009], GastroPlus, PopGen [McNally *et al.* 2014], P3M [Price *et al.* 2003], physB [Bosgra *et al.* 2012], etc.)

*Predict* physiological TK quantities (as used by generic TK model) for each individual:


Tissue masses  
Tissue blood flows  
GFR (kidney function)  
Hepatocellularity

# Chemical-specific parameters have both uncertainty and variability


Chemical-specific parameters	
Intrinsic hepatic clearance rate (CL <sub>int</sub> )	Carry uncertainty from <i>in vitro</i> measurements  <b>Also</b> have population variability: represent chemical-body interactions — vary with individual genetics, environmental factors, age, etc.
Fraction unbound to plasma protein (F <sub>up</sub> )	

# Chemical-specific TK parameters: Two-stage Monte Carlo approach to modeling both *measurement uncertainty* and *population variability*

Step 1: Draw 1 sample from uncertainty distribution and treat as “population average” value




Step 2: Assume population variability (30% CV) around the sampled “population average” value from Step 1, and draw 1 sample



For CLint: Add 5% “poor metabolizers” (10% of original pop. average)

Repeat Steps 1 and 2 for each simulated individual to get sampled values that include both uncertainty & variability



11/11/2019




# httk R package automates this Monte Carlo sampling & model evaluation process

```
> library(httk)
> set.seed(42)
> #Css for 1 mg/kg/day = slope
  calc_mc_css(chem.name="benzo(a)pyrene",
              which.quantile = c(0.95, 0.5, 0.05))
```


Human plasma concentration returned in mg/L units  
for 0.95 0.5 0.05 quantile.

95%	50%	5%
68.510	13.070	3.742

# Result: Percentiles of predicted $C_{ss}$ vs. dose slope



Another way to visualize: ratio of 95<sup>th</sup> percentile to median  
(roughly, how wide is the Css slope distribution?)



# Relative contributions of variability & uncertainty





Figure adapted from Wambaugh et al. (2019)

# Simulating sensitive subpopulations

# Identifying potentially sensitive sub-populations



Who is in the most sensitive portion of the population?

What does this slope distribution look like for kids, for example?

Or people over 65?

To answer this question: Need to model TK variability for specified sub-populations

# HTTK-Pop can generate simulated subpopulations with user-specified demographics


Use `httkpop.generate.args` argument to `calc_mc_css()` function: Takes a named list of arguments

Name of list element	User can specify...	Example		Default if not specified
<code>agelim_years</code>	Age limits in years	<code>c(6, 11)</code>	Ages 6-11 years	All NHANES (0-79 years)
<code>agelim_months</code>	Age limits in months	<code>c(0, 36)</code>	Ages 0-36 months	All NHANES (0-79 years)
<code>gendernum</code>	# of males and females	<code>list(Male = 1000, Female = 0)</code>	1000 males, 0 females	Randomly selected from NHANES
<code>weight_category</code>	BMI category	<code>c('Overweight', 'Obese')</code>	BMI > 25 (overweight & obese)	<code>c('Underweight', 'Normal', 'Overweight', 'Obese')</code>

HTTK-Pop generates physiology based on NHANES respondents in the specified demographic groups




# Example of C<sub>ss</sub>95 differences by subpopulation



10 subgroups of interest

Heatmap: C<sub>ss</sub>95 difference (subgroup vs. Total population) for 50 chemicals with largest C<sub>ss</sub>95 difference in *any* subgroup



# Conclusions

# Conclusions

- Uncertainty vs. Variability in TK model parameters
  - Measurement uncertainty: Chemical-specific parameters measured *in vitro*
  - Population variability: Physiological & chemical-specific parameters
- Characterizing key uncertainty in chemical-specific TK parameters
  - Fraction unbound in plasma protein (Fup)
  - Intrinsic hepatic clearance rate (Clint)
- Characterizing variability: HTK-Pop for human TK variability
  - Correlated Monte Carlo approach based on CDC NHANES data
- Relative contributions of uncertainty and variability to TK model predictions
  - For most chemicals, population variability has larger effect
- Simulating sensitive subpopulations
  - HTK-Pop can simulate populations with user-specified demographics

# Thank you!

Questions?



# References

1. Rotroff DM, Wetmore BA, Dix DJ, et al. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. *Toxicological Sciences*. 2010;117(2):348-358
2. Wetmore BA, Wambaugh JF, Allen B, et al. Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing. *Toxicological Sciences*. 2015 Nov;148(1):121-36
3. Wambaugh JF, Wetmore BA, Pearce R, Strope C, Goldsmith R, Sluka JP, et al. Toxicokinetic Triage for Environmental Chemicals. *Toxicol Sci*. 2015;147(1):55-67.
4. Ring CL, Pearce RG, Setzer RW, et al. Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability. *Environment International*. 2017 2017/09/01/;106:105-118.
5. Shibata Y, Takahashi H, Chiba M, Ishii Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. *Drug Metab Dispos*. 2002;30(8):892-6.
6. Waters NJ, Jones R, Williams G, Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. *J Pharm Sci*. 2008;97(10):4586-95.
7. Wetmore BA, Wambaugh JF, Ferguson SS, et al. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. *Toxicological Sciences*. 2012 Jan;125(1):157-74.
8. Wetmore BA. Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. *Toxicology*. 2015;332:94-101.

9. Wambaugh JF, Wetmore BA, Ring CL, Nicolas CI, Pearce RG, Honda GS, et al. Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization. *Toxicol Sci.* 2019;172(2):235-51.
10. Sipes NS, Wambaugh JF, Pearce R, et al. An Intuitive Approach for Predicting Potential Human Health Risk with the Tox21 10k Library. *Environmental Science & Technology.* 2017 2017/09/19;51(18):10786-10796.
11. Pearce RG, Setzer RW, Davis JL, Wambaugh JF. Evaluation and calibration of high-throughput predictions of chemical distribution to tissues. *J Pharmacokinet Pharmacodyn.* 2017b;44(6):549-65.
12. Jamei M, Marciniak S, Feng K, et al. The Simcyp® population-based ADME simulator. *Expert Opinion on Drug Metabolism & Toxicology.* 2009;5(2):211-223.
13. McNally K, Cotton R, Hogg A, Loizou G. PopGen: A virtual human population generator. *Toxicology.* 2014;315:70-85.
14. Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET, et al. Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans. *Critical Reviews in Toxicology.* 2003;33(5):469-503.
15. Bosgra S, van Eijkeren J, Bos P, Zeilmaker M, Slob W. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. *Crit Rev Toxicol.* 2012;42(9):751-67.
16. Wetmore BA, Allen B, Clewell HJ, 3rd, et al. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. *Toxicological Sciences.* 2014 Nov;142(1):210-24.